These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12713613)

  • 21. Tegaserod maleate (Zelnorm) for IBS with constipation.
    Med Lett Drugs Ther; 2002 Sep; 44(1139):79-80. PubMed ID: 12237618
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.
    Bardhan KD; Forbes A; Marsden CL; Mason T; Short G
    Aliment Pharmacol Ther; 2004 Jul; 20(2):213-22. PubMed ID: 15233702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky.
    Horwitz BJ
    Health News; 2002 Oct; 8(10):1-2. PubMed ID: 12416480
    [No Abstract]   [Full Text] [Related]  

  • 26. Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials.
    Schoenfeld P
    Aliment Pharmacol Ther; 2004 Feb; 19(3):263-9. PubMed ID: 14984372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tegaserod.
    Scott LJ; Perry CM
    Drugs; 1999 Sep; 58(3):491-6; discussion 497-8. PubMed ID: 10493276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New drugs to treat irritable bowel syndrome being tested.
    Mayo Clin Health Lett; 2000 Mar; 18(3):4. PubMed ID: 10734837
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
    Appel-Dingemanse S
    Clin Pharmacokinet; 2002; 41(13):1021-42. PubMed ID: 12403641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
    Prather CM; Camilleri M; Zinsmeister AR; McKinzie S; Thomforde G
    Gastroenterology; 2000 Mar; 118(3):463-8. PubMed ID: 10702196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Desperately seeking serotonin... A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders.
    Pasricha PJ
    Gastroenterology; 2007 Jun; 132(7):2287-90. PubMed ID: 17570201
    [No Abstract]   [Full Text] [Related]  

  • 33. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials.
    Müller-Lissner S; Koch G; Talley NJ; Drossman D; Rueegg P; Dunger-Baldauf C; Lefkowitz M
    J Clin Epidemiol; 2003 Apr; 56(4):310-6. PubMed ID: 12767407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome.
    McGahan L
    Issues Emerg Health Technol; 2000 Oct; (11):1-5. PubMed ID: 11902219
    [No Abstract]   [Full Text] [Related]  

  • 36. Tegaserod: a new 5-HT(4) agonist in the treatment of irritable bowel syndrome.
    Corsetti M; Tack J
    Expert Opin Pharmacother; 2002 Aug; 3(8):1211-8. PubMed ID: 12150698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contemporary thoughts on the treatment of irritable bowel syndrome.
    Giaquinta D
    Manag Care Interface; 2002 Aug; 15(8):19-20, 22. PubMed ID: 12229060
    [No Abstract]   [Full Text] [Related]  

  • 38. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
    Nyhlin H; Bang C; Elsborg L; Silvennoinen J; Holme I; Rüegg P; Jones J; Wagner A
    Scand J Gastroenterol; 2004 Feb; 39(2):119-26. PubMed ID: 15000272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tegaserod in patients with irritable bowel syndrome.
    Schooff M; Stelter C
    Am Fam Physician; 2004 Dec; 70(11):2107-8. PubMed ID: 15606056
    [No Abstract]   [Full Text] [Related]  

  • 40. Tegaserod and other serotonergic agents: what is the evidence?
    Chey WD
    Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.